Akebia Therapeutics Inc (AKBA)
1.37
0.00 (0.00%)
USD |
NASDAQ |
Apr 24, 16:00
1.37
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Enterprise Value: 278.60M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 278.60M |
| April 23, 2024 | 278.60M |
| April 22, 2024 | 276.50M |
| April 19, 2024 | 276.50M |
| April 18, 2024 | 282.79M |
| April 17, 2024 | 282.79M |
| April 16, 2024 | 284.88M |
| April 15, 2024 | 282.79M |
| April 12, 2024 | 297.44M |
| April 11, 2024 | 312.10M |
| April 10, 2024 | 318.38M |
| April 09, 2024 | 314.19M |
| April 08, 2024 | 312.10M |
| April 05, 2024 | 303.72M |
| April 04, 2024 | 307.91M |
| April 03, 2024 | 303.72M |
| April 02, 2024 | 322.57M |
| April 01, 2024 | 333.03M |
| March 28, 2024 | 374.91M |
| March 27, 2024 | 460.75M |
| March 26, 2024 | 410.50M |
| March 25, 2024 | 454.47M |
| March 22, 2024 | 446.10M |
| March 21, 2024 | 418.88M |
| March 20, 2024 | 397.94M |
| Date | Value |
|---|---|
| March 19, 2024 | 374.91M |
| March 18, 2024 | 387.47M |
| March 15, 2024 | 347.69M |
| March 14, 2024 | 278.60M |
| March 13, 2024 | 286.97M |
| March 12, 2024 | 268.07M |
| March 11, 2024 | 271.96M |
| March 08, 2024 | 277.79M |
| March 07, 2024 | 275.85M |
| March 06, 2024 | 281.69M |
| March 05, 2024 | 303.09M |
| March 04, 2024 | 306.98M |
| March 01, 2024 | 324.49M |
| February 29, 2024 | 299.20M |
| February 28, 2024 | 291.42M |
| February 27, 2024 | 310.87M |
| February 26, 2024 | 285.58M |
| February 23, 2024 | 254.44M |
| February 22, 2024 | 262.23M |
| February 21, 2024 | 268.07M |
| February 20, 2024 | 271.96M |
| February 16, 2024 | 273.90M |
| February 15, 2024 | 277.79M |
| February 14, 2024 | 289.47M |
| February 13, 2024 | 287.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-32.82M
Minimum
Nov 29 2022
1.776B
Maximum
Jun 29 2020
377.08M
Average
299.98M
Median
Jan 31 2022
Enterprise Value Benchmarks
| Ocugen Inc | 266.98M |
| Aquestive Therapeutics Inc | 289.53M |
| SELLAS Life Sciences Group Inc | 84.12M |
| Protagonist Therapeutics Inc | 1.156B |
| Stoke Therapeutics Inc | 338.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.614M |
| Revenue (Quarterly) | 56.20M |
| Total Expenses (Quarterly) | 54.82M |
| Gross Profit Margin (Quarterly) | 66.79% |
| Profit Margin (Quarterly) | 1.09% |
| Earnings Yield | -20.44% |
| Normalized Earnings Yield | -20.16 |